TABLE 3.
Comparative sensitivities of the Pgp3 assay and commercial ELISAs
| Patient group and assay | No. of samples from C. trachomatis- positive patients | Sensitivity (%) (95% CI) | Difference in sensitivity between the Pgp3 assay and the commercial assaya (%) (95% CI) | McNemar's P value |
|---|---|---|---|---|
| All patients | ||||
| Pgp3 | 356 | 57.9 (52.7-62.9) | ||
| Ani Labsystems | 356 | 49.2 (44.0-54.3) | 8.7 (2.9-14.5) | 0.003 |
| SeroCT | 356 | 47.2 (42.1-52.4) | 10.7 (4.9-16.5) | <0.0005 |
| Medac | 356 | 44.4 (39.3-49.6) | 13.5 (7.0-20.0) | <0.0005 |
| Femalesb | ||||
| Pgp3 | 164 | 73.8 (66.5-79.9) | ||
| Ani Labsystems | 164 | 59.8 (52.1-67.0) | 14.0 (5.5-22.5) | 0.001 |
| SeroCT | 164 | 55.5 (47.8-62.9) | 18.3 (10.1-26.5) | <0.0005 |
| Medac | 164 | 45.7 (38.3-53.4) | 28.0 (18.9-37.2) | <0.0005 |
| Malesb | ||||
| Pgp3 | 190 | 44.2 (37.3-51.3) | ||
| Ani Labsystems | 190 | 40.5 (33.8-47.6) | 3.7 (−4.5-11.8) | 0.42 |
| SeroCT | 190 | 40.0 (33.3-47.1) | 4.2 (−4.1-12.6) | 0.36 |
| Medac | 190 | 43.7 (36.8-50.8) | 0.5 (−8.6-9.6) | 1.00 |
a
The sensitivity of the commercial assay was subtracted from that of the Pgp3 assay.
b
P values for differences in sensitivity on male versus female sera are as follows: for the Pgp3 test, <0.0005; for the Ani Labsystems assay, <0.0005; for the SeroCT assay, 0.004; and for the Medac assay, 0.75.